Biogen Idec Research Limited

Neurodegenerative disease and motor neuron disorders

Research activity includes spinal muscular atrophy, amyotrophic lateral sclerosis linked to SOD1 mutation, Parkinson’s disease, and mild cognitive impairment due to Alzheimer’s disease.

  • Spinal muscular atrophy
  • Amyotrophic lateral sclerosis with SOD1 mutation
  • Parkinson’s disease
  • Alzheimer’s disease–related cognitive decline

The portfolio also extends to long-term neurological follow-up and treatment persistence in inherited and progressive nervous system disorders.

Multiple sclerosis and central nervous system inflammation

Clinical research covers relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis and pediatric RRMS, with attention to inflammatory activity within the central nervous system.

  • Relapsing-remitting multiple sclerosis
  • Relapsing forms of multiple sclerosis
  • Pediatric multiple sclerosis
  • Brain inflammation and MRI-defined disease activity

Work in this area also includes continued evaluation of disease control and longer-term neurological outcomes.

Lupus and cutaneous autoimmune disease

The sponsor funds studies in systemic lupus erythematosus, subacute cutaneous lupus erythematosus, and chronic cutaneous lupus erythematosus, including cases with systemic features and refractory skin disease.

  • Systemic lupus erythematosus
  • Subacute cutaneous lupus erythematosus
  • Chronic cutaneous lupus erythematosus
  • Autoimmune skin and systemic manifestations

These studies focus on both skin activity and broader autoimmune involvement in adult populations.

Kidney transplantation and immune-mediated renal disease

Research includes kidney transplant recipients with late antibody-mediated rejection and microvascular inflammation, alongside primary renal autoimmunity such as IgA nephropathy.

  • Late antibody-mediated rejection
  • Late isolated microvascular inflammation
  • IgA nephropathy
  • Transplant-related immune injury

The renal portfolio reflects interest in both post-transplant complications and chronic immune-driven kidney disease.

Inherited retinal disease and rare genetic disorders

Additional studies address choroideremia, X-linked retinitis pigmentosa, and Friedreich’s ataxia, highlighting involvement in inherited conditions affecting vision and neurology.

  • Choroideremia
  • X-linked retinitis pigmentosa
  • Friedreich’s ataxia
  • Rare genetic disease

These programs include disorders with progressive sensory, retinal, and neurologic impairment.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • A study testing omaveloxolone compared to placebo for children and adolescents aged 2 to 15 years with Friedreich’s ataxia

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Denmark France Germany Ireland Italy +2
  • Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Greece +7
  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    3 1 1
    Investigated diseases:
    Belgium Bulgaria Croatia Czechia France Germany +5
  • Study on How Nusinersen is Processed in Adults and Children with Spinal Muscular Atrophy Using the ThecaFlex DRx System

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain
  • Long-term Safety and Efficacy Study of Gene Therapy for Choroideremia and X-Linked Retinitis Pigmentosa Using AAV2-REP1 and AAV8-RPGR in Previously Treated Patients

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany
  • Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

    Recruiting

    4 1
    Investigated drugs:
    Belgium Bulgaria France Germany Hungary Italy +5